Brought to you by 
AZ and MedImmune get exclusive rights from Innate; deal expanded
30 Jan 2023
Executive Summary
AstraZeneca PLC and its biologics division MedImmune LLC licensed exclusive global rights to develop and sell a cancer therapy combining their MEDI4736 with Innate Pharma SA’s IPH2201. AZ also gets access to IPH2201 as a monotherapy and combo treatment in other undisclosed areas.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Immuno-Oncology
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- Includes Equity
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
AZ and MedImmune get exclusive rights from Innate; deal expanded
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice